Jacopo Giuliani1, Andrea Bonetti1. 1. Department of Oncology, Mater Salutis Hospital, Az. ULSS 9 Scaligera, Legnago (VR), Italy.
Abstract
Introduction: The present evaluation was restricted to pivotal phase III randomized controlled trials (RCTs) in first-line for metastatic non-small cell lung cancer (NSCLC). Materials and methods: We calculated the pharmacological costs necessary to get the benefit in overall survival (OS), for each trial. Results: Our analysis evaluated 10 phase III RCTs, including 9485 patients. The most relevant increase of cost € per month of OS-gain was associated with bevacizumab (66,720 €) and the lowest with the use of pembrolizumab (2734 €). Conclusion: Combining pharmacological costs of drugs with the measure of efficacy represented by OS, pembrolizumab is a cost-effective first-line treatment for patients with metastatic NSCLC.
Introduction: The present evaluation was restricted to pivotal phase III randomized controlled trials (RCTs) in first-line for metastatic non-small cell lung cancer (NSCLC). Materials and methods: We calculated the pharmacological costs necessary to get the benefit in overall survival (OS), for each trial. Results: Our analysis evaluated 10 phase III RCTs, including 9485 patients. The most relevant increase of cost € per month of OS-gain was associated with bevacizumab (66,720 €) and the lowest with the use of pembrolizumab (2734 €). Conclusion: Combining pharmacological costs of drugs with the measure of efficacy represented by OS, pembrolizumab is a cost-effective first-line treatment for patients with metastatic NSCLC.
Authors: Meng-Meng Teng; Si-Ying Chen; Bo Yang; Yan Wang; Rui-Ying Han; Meng-Na An; Ya-Lin Dong; Hai-Sheng You Journal: Cancer Med Date: 2021-08-12 Impact factor: 4.452